Evomela Generic Name & Formulations
Melphalan HCl 50mg/vial; lyophilized pwd; for IV infusion after reconstitution.
Single-dose vial (20mL)—1
High-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Evomela Dosage and Administration
Give prophylactic antiemetics. Give by IV infusion over 30mins. 100mg/m2 daily for 2 consecutive days (Days -3 and -2) prior to transplantation (Day 0). If patient weighs >130% of their ideal body weight, use adjusted ideal body weight.
Evomela Boxed Warnings
Severe bone marrow suppression. Hypersensitivity. Leukemogenicity.
Bone marrow suppression. Monitor CBCs, provide supportive care for infections, anemia, thrombocytopenia until adequate recovery. GI toxicity; provide supportive care. Monitor LFTs. Renal impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
Caution with cyclosporine, BCNU.
Evomela Adverse Reactions
Decreased neutrophil, WBC, lymphocyte, and platelet counts, diarrhea, nausea, fatigue, hypokalemia, anemia, vomiting; mucositis, hypersensitivity reactions, hepatic disorders, secondary malignancies, infertility.
Evomela Clinical Trials
Evomela Patient Counseling